Dr. Brufsky Discusses Future Research into Bisphosphonates

Adam M. Brufsky, MD, PhD
Published: Monday, Aug 11, 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

The cancer cell itself is incredibly complex, Brufsky says. Much work has been done to understand cancer cells with next-generation sequencing and RNA-based assays.

Drugs like bisphosphonates and denosumab affect the host greatly. Research needs to be conducted focused on the genomics of the host and the factors that allow metastatic disease to come about from the host’s perspective.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

The cancer cell itself is incredibly complex, Brufsky says. Much work has been done to understand cancer cells with next-generation sequencing and RNA-based assays.

Drugs like bisphosphonates and denosumab affect the host greatly. Research needs to be conducted focused on the genomics of the host and the factors that allow metastatic disease to come about from the host’s perspective.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x